We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$261M
1-Year Est. Return
78.99%
This Fund
S&P 500
This Quarter
Est. Return
+15.01%
1 Year Est. Return
+78.99%
3 Year Est. Return
+177.36%
5 Year Est. Return
+206.33%
10 Year Est. Return
+684.02%
AUM
$115M
AUM Growth
+$35.6M
(+45%)
Cap. Flow
+$33.1M
Cap. Flow
% of AUM
28.7%
Top 10 Holdings %
Top 10 Hldgs %
16.88%
Holding
267
New
23
Increased
109
Reduced
60
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$1.39M |
| 2 |
iShares MSCI India ETF
INDA
|
+$872K |
| 3 |
Iovance Biotherapeutics
IOVA
|
+$767K |
| 4 |
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
|
+$708K |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$648K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ProShares Ultra Utilities
UPW
|
+$1.11M |
| 2 |
Vanguard Energy ETF
VDE
|
+$755K |
| 3 |
RXDX
Ignyta, Inc.
RXDX
|
+$612K |
| 4 |
Fidelity MSCI Information Technology Index ETF
FTEC
|
+$430K |
| 5 |
JUNO
Juno Therapeutics, Inc.
JUNO
|
+$359K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.89% |
| 2 | Miscellaneous | 12.04% |
| 3 | Financials | 0.81% |
| 4 | Technology | 0.51% |
| 5 | Consumer Discretionary | 0.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
iShares 20+ Year Treasury Bond ETF
TLT
$46.6B
| $3.32M | 2.88% |
27,200
+11,511
| +73% | +$1.39M |
|
|
2
Fidelity MSCI Information Technology Index ETF
FTEC
$21.3B
| $3.22M | 2.79% |
62,005
-8,112
| -12% | -$430K |
|
|
VPU
3
Vanguard Utilities ETF
VPU
$8.33B
| $2.55M | 2.22% |
22,845
-225
| -1% | -$24.8K |
|
4
Geron
GERN
$1.01B
| $1.61M | 1.4% |
379,430
+204,747
| +117% | +$553K |
|
5
Nektar Therapeutics
NKTR
$2.53B
| $1.59M | 1.38% |
1,001
-125
| -11% | -$161K |
|
|
6
Iovance Biotherapeutics
IOVA
$3.98B
| $1.54M | 1.33% |
90,926
+50,667
| +126% | +$767K |
|
7
Direxion Daily Financial Bull 3x ETF
FAS
$2.4B
| $1.51M | 1.31% |
23,570
+117
| +0.5% | +$8.35K |
|
|
GTHX
8
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $1.41M | 1.23% |
38,125
+20,478
| +116% | +$546K |
|
|
ONC
9
BeOne Medicines Ltd
ONC
$40.5B
| $1.36M | 1.18% |
8,082
+4,349
| +117% | +$589K |
|
|
ONCE
10
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $1.33M | 1.16% |
20,024
-1,172
| -6% | -$67.7K |
|
|
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $1.32M | 1.15% |
43,136
+23,350
| +118% | +$648K |
|
|
JNCE
12
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $1.32M | 1.14% |
58,867
+31,919
| +118% | +$708K |
|
13
TG Therapeutics
TGTX
$8.57B
| $1.28M | 1.11% |
89,920
+48,087
| +115% | +$615K |
|
14
PTC Therapeutics
PTCT
$5.78B
| $1.27M | 1.1% |
46,917
+25,165
| +116% | +$638K |
|
15
Enanta Pharmaceuticals
ENTA
$410M
| $1.26M | 1.1% |
15,613
-1,918
| -11% | -$148K |
|
|
MNTA
16
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $1.24M | 1.08% |
68,484
-4,063
| -6% | -$67.7K |
|
|
17
iShares MSCI India ETF
INDA
$6.75B
| $1.24M | 1.08% |
36,402
+24,558
| +207% | +$872K |
|
18
Sarepta Therapeutics
SRPT
$2.38B
| $1.22M | 1.06% |
16,409
-1,488
| -8% | -$99.2K |
|
|
CBAY
19
DELISTED
Cymabay Therapeutics
CBAY
| $1.21M | 1.05% |
93,317
+50,832
| +120% | +$632K |
|
20
Novavax
NVAX
$1.69B
| $1.19M | 1.03% |
28,227
+14,967
| +113% | +$601K |
|
|
IMGN
21
DELISTED
Immunogen Inc
IMGN
| $1.18M | 1.03% |
112,547
+58,570
| +109% | +$579K |
|
22
Agios Pharmaceuticals
AGIO
$1.98B
| $1.18M | 1.02% |
14,405
+7,781
| +117% | +$601K |
|
23
Madrigal Pharmaceuticals
MDGL
$12.5B
| $1.13M | 0.98% |
9,629
+5,247
| +120% | +$648K |
|
|
ARRY
24
DELISTED
Array Biopharma Inc
ARRY
| $1.12M | 0.97% |
68,763
+36,645
| +114% | +$587K |
|
25
Ligand Pharmaceuticals
LGND
$5.69B
| $1.12M | 0.97% |
10,854
-625
| -5% | -$61.8K |
|
Similar funds
BW
HFS
NFG
NI
FAM
TAM
SBCM
RF
Virtus ETF Advisers's Q1 2018 Portfolio in Review
As of Q1 2018, Virtus ETF Advisers held 267 positions worth $115M, up 45% from $79.7M the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Virtus ETF Advisers deployed $33.1M of net new capital in Q1 2018, opening 23 new positions and adding to 109 existing holdings. Its largest new stake was Sociedad Química y Minera de Chile: 2,101 shares worth $103K.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 79% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Vanguard Energy ETF, an estimated $755K trimmed.
- Virtus ETF Advisers's largest Q1 2018 buy was Sociedad Química y Minera de Chile: 2,101 shares worth $103K.
- Virtus ETF Advisers added most to iShares 20+ Year Treasury Bond ETF in Q1 2018, an estimated $1.39M increase.
- Virtus ETF Advisers's biggest Q1 2018 reduction was Vanguard Energy ETF, cutting an estimated $755K.
- Virtus ETF Advisers fully exited ProShares Ultra Utilities in Q1 2018, selling an estimated $1.11M.
- Virtus ETF Advisers's ten largest holdings make up 17% of its $115M portfolio in Q1 2018.
- Virtus ETF Advisers opened 23 new positions and closed 21 in Q1 2018.
- Virtus ETF Advisers's portfolio value rose 45% quarter-over-quarter to $115M.
Based on Virtus ETF Advisers's 13F filing for Q1 2018, filed 14 May 2018.